Community Reinvestment Act regulations
Abstract:The OCC, the Board, the FDIC, and the OTS (collectively, ‘‘the agencies’’) are adopting revisions to our rules implementing the Community Reinvestment Act (CRA). The agencies are revising the term ‘‘community development’’ to include loans, investments, and services by financial institutions that support, enable, or facilitate projects or activities that meet the ‘‘eligible uses’’ criteria described in Section 2301(c) of the Housing and Economic Recovery Act of 2008 (HERA), as amended, and are conducted in designated target areas identified in plans approved by the United States Department of Housing and Urban Development (HUD) under the Neighborhood Stabilization Program (NSP).
The final rule provides favorable CRA consideration of such activities that, pursuant to the requirements of the program, benefit low-, moderate-, and middle-income individuals and geographies in NSP target areas designated as ‘‘areas of greatest need.’’ Covered activities are considered both within an institution’s assessment area(s) and outside of its assessment area(s), as long as the institution has adequately addressed the community development needs of its assessment area(s). Favorable consideration under the revised rule will be available until no later than two years after the last date appropriated funds for the program are required to be spent by the grantees.
Effective Date: This joint final rule is effective January 19, 2011.
Click here to download the file
Trending Compliance Trainings
Sterile Filtration of Pharmaceutical Products - Validation and Regulatory Requirements
By - Roger Cowan
On Demand Access Anytime
By - Roger Cowan
On Demand Access Anytime
FFIEC BSA/AML Examination Manual: What Compliance Officers Really Need to Know?
By - Doug Keipper
On Demand Access Anytime
By - Doug Keipper
On Demand Access Anytime
Technical Writing for the Pharmaceutical, Medical Device and Biotech Industries
By - Joy McElroy
On Demand Access Anytime
By - Joy McElroy
On Demand Access Anytime
Trial Master File and Clinical Data Management Regulated by FDA
By - Carolyn Troiano
On Demand Access Anytime
By - Carolyn Troiano
On Demand Access Anytime
Good Documentation Practice and Record Keeping Regulations (FDA & EMA)
By - Dr. Afsaneh Motamed Khorasani
On Demand Access Anytime
By - Dr. Afsaneh Motamed Khorasani
On Demand Access Anytime
Understanding and Preparing for FDA Pharmaceutical Inspections
By - Michael Ferrante
On Demand Access Anytime
By - Michael Ferrante
On Demand Access Anytime
You Recently Viewed
